A Retrospective Study of the Feasibility and Safety of Endoscopic Control in Patients with Serrated Polyposis Syndrome

Efficacy and Safety of Endoscopic Treatment for Patients with Serrated Polyposis Syndrome (SPS) - Efficacy and Safety of Endoscopic Treatment for Patients with Serrated Polyposis Syndrome (SPS)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050303

Enrollment

Registered

2023-02-10

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serrated Polyposis Syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who fulfilled SPS diagnostic criteria defined by the World Health Organization (WHO) in 2019 in their fifth edition of the Classification of Tumors of the Digestive System I) At least 5 serrated lesions/polyps proximal to the rectum, all 5 mm or more in size, with at least 2 being 10 mm or more in size II) At least 20 serrated lesions/polyps of any size distributed throughout the large bowel, with at least 5 being proximal to the rectum

Exclusion criteria

Exclusion criteria: The patients with known inflammatory bowel disease

Design outcomes

Primary

Measure	Time frame
The achievement rate of endoscopic control(EC) (achieving EC was defined as complete polyp removal (all polyps larger than 3 mm) accomplished by endoscopic treatment alone)	—

Secondary

Measure	Time frame
The endoscopic treatment combination used to achieve EC, treatment-related adverse events, and detection of advanced neoplasia (colorectal cancer, sessile serrated lesions with dysplasia and advanced adenoma, advanced serrated lesions) during the surveillance phase	—

Countries

Japan

Contacts

Public ContactMichiko Nakaoka

Omori Red Cross Hospital Gastroenterology

michiko_cinnamon@ybb.ne.jp+81-3-3775-3111

Outcome results